Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by various company officials on October 4, 2012. These acquisitions were executed at a price of 1460.066 pence per share. The transactions resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan.
- Sir Andrew Witty: Acquired 24 Ordinary Shares
- Mr S M Bicknell: Acquired 13 Ordinary Shares
- Mr R G Connor: Acquired 28 Ordinary Shares
- Mr S Dingemans: Acquired 3 Ordinary Shares
- Mr S A Hussain: Acquired 7 Ordinary Shares
- Dr D Pulman: Acquired 11 Ordinary Shares
- Mr D S Redfern: Acquired 13 Ordinary Shares
- Ms C Thomas: Acquired 13 Ordinary Shares
- Mr P C Thomson: Acquired 16 Ordinary Shares
- Dr P J T Vallance: Acquired 17 Ordinary Shares
- Mrs V A Whyte: Acquired 22 Ordinary Shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of director share interests.
Investor Verification Checklist
- Verify the share price of 1460.066 pence per Ordinary Share on October 4, 2012.
- Confirm the total number of shares acquired by each listed director through the ShareReward Plan.
- Review the company's broader financial reports (e.g., Form 20-F) for actual revenue and profit metrics, as they are absent in this filing.